The future beyond blood pressure measurement - Shaping the future of cardiovascular health towards predictive medicine with our medical-grade algorithms for cardiovascular diagnostics.
3 years after company foundation we launched our first invasively validated medical algorithm in spring 2020, leading to first revenue with our first B2B customer by implementation into his product line for cardiology practices. Besides increasing sales of this product line, we are in negotiations or market entry preparations with over 5 other customers. To date, we are financed by 2M € Seed stage VC and Horizon Europe. We just opened our Series-A stage for targeting new international customers to set up the stage for future algorithms, mainly for cuffless and contactless medical applications.
Problem or Opportunity
In the last 150 years, our life span has doubled. Blood pressure measurement (BPM) contributed greatly to this and is still the most frequently performed medical examination worldwide. Nevertheless, the last 25 years of life are dominated by cardiovascular diseases. BPM is inadequate to help minimizing those years and increase the health span instead, because it only detects a problem when it is already established, i.e. high blood pressure and underlying vessel damage are already pronounced. Now it is time to maximise the health span: the period during which we live free of chronic diseases.
Solution (product or service)
The solution is to determine the cardiovascular phenotype instead of blood pressure values, based on analysing the underlying biosignal: the pulse wave. Pulse wave analysis interprets the entire topography, shape and characteristics of the pulse waves. Thus, it detects underlying changes of heart, vessels or hemodynamic regulation long before the blood pressure rises and enables any form of individual preventive therapy. Pulse wave phenotyping can be used anywhere blood pressure is measured today: as a single measurement e.g. in doctor's offices, clinics, and as trend monitoring at home.
Our business model is quantity-based B2B software licencing modules of our medical algorithms with fixed quarterly pre-payments. We also offer pay-per-use, which is interesting for future telemedicine integrations and e-health platforms. Additionally, affiliations for therapy provides are a future revenue potential. In terms of technology commercialization: our Antares algorithm for cuff-based measurement of central blood pressure and pulse wave velocity is commercially available in the first devices of our customers. On the medical side, it is validated against the invasive gold standard.